Strategic Capital Advisers’s AbbVie ABBV Stock Holding History

Strategic Capital Advisers’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$283K	Buy	1,846 +6	+0.3%	+$917	0.23%	51
2022 Q1	$298K	Buy	1,840 +6	+0.3%	+$872	0.23%	50
2021 Q4	$248K	Buy	+1,834	New	+$217K	0.18%	53
2020 Q2	–	Sell	-2,959	Closed	-$225K	–	50
2020 Q1	$225K	Buy	2,959 +130	+5%	+$11.1K	0.27%	47
2019 Q4	$250K	Buy	2,829 +28	+1%	+$2.33K	0.23%	57
2019 Q3	$212K	Buy	2,801 +15	+0.5%	+$1.03K	0.24%	55
2019 Q2	$203K	Buy	2,786 +30	+1%	+$2.36K	0.21%	55
2019 Q1	$222K	Buy	2,756 +530	+24%	+$43.4K	0.24%	52
2018 Q4	$205K	Buy	2,226 +24	+1%	+$2.11K	0.22%	51
2018 Q3	$208K	Buy	2,202 +21	+1%	+$1.99K	0.15%	57
2018 Q2	$212K	Buy	2,181 +33	+2%	+$3.22K	0.16%	57
2018 Q1	$208K	Hold	2,148	–	–	0.21%	58
2017 Q4	$208K	Buy	+2,148	New	+$202K	0.2%	59

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Strategic Capital Advisers's ABBV Position: Q2 2022 in Review

Strategic Capital Advisers increased its AbbVie (ABBV) stake by 0.33% in Q2 2022, buying an estimated $917 and bringing the position to 1,846 shares worth $283K. The position accounts for 0.23% of the portfolio, ranked #51.

Strategic Capital Advisers first reported a position in ABBV in Q4 2017 and has held it in 13 quarters since. The position peaked at $298K in Q1 2022. 3,006 funds tracked by Wall St. Rank hold ABBV as of Q2 2022.

Strategic Capital Advisers held 1,846 shares of AbbVie worth $283K as of Q2 2022.
Strategic Capital Advisers bought 6 AbbVie shares in Q2 2022, an estimated $917.
AbbVie made up 0.23% of Strategic Capital Advisers's portfolio in Q2 2022, its #51 holding.
Strategic Capital Advisers first reported a position in AbbVie in Q4 2017 and has held it in 13 quarters since.
Strategic Capital Advisers's AbbVie position peaked at $298K in Q1 2022.
3,006 funds tracked by Wall St. Rank held AbbVie as of Q2 2022.

Based on Strategic Capital Advisers's 13F filing for Q2 2022, filed 18 Jul 2022.